Robin Horn, MD
Cardiovascular Disease · Newark, DENPI 1609842608
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Lantheus Medical Imaging, Inc. at 58.9% of the total. Reporting peaked in 2020 at $4,923 and has fallen 77.3% since, to $1,119 in 2025.
Across 229 payments — averaging $41.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lantheus Medical Imaging, Inc.$6K
- Johnson & Johnson$487
- Boehringer Ingelheim$469
- Pfizer$402
- Amgen$321
- Novartis$314
- plus $2K from 24 others
What the payments were for
- Speaking & faculty fees$4,50047%
- Travel & lodging$4945%
- Food & beverage$4,54248%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lantheus Medical Imaging, Inc. | 19 | $5,626 |
| Johnson & Johnson | 36 | $487 |
| Boehringer Ingelheim | 30 | $469 |
| Pfizer | 20 | $402 |
| Amgen | 17 | $321 |
| Novartis | 19 | $314 |
| AstraZeneca | 18 | $305 |
| AOP Health US, LLC | 1 | $237 |
| E.r. Squibb & Sons, L.L.C. | 17 | $234 |
| Heartflow, Inc. | 5 | $187 |
| Alnylam Pharmaceuticals Inc. | 5 | $120 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $119 |
| Sanofi-aventis U.S. LLC | 6 | $92 |
| Philips North America LLC | 3 | $86 |
| Bayer | 2 | $57 |
| Abbott | 2 | $56 |
| Regeneron Healthcare Solutions, Inc. | 4 | $56 |
| Merck | 3 | $54 |
| Kowa Pharmaceuticals America, Inc. | 3 | $42 |
| Boston Scientific | 2 | $36 |
| Preventice Services, LLC | 1 | $36 |
| Siemens Medical Solutions USA, Inc. | 2 | $33 |
| Medtronic | 1 | $31 |
| Bardy Diagnostics, Inc. | 1 | $30 |
| Sanofi | 1 | $28 |
| Abiomed | 1 | $25 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $19 |
| Ionis Pharmaceuticals, Inc. | 1 | $18 |
| Bridgebio Pharma, Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,550 in reported general payments places this provider in the 75th percentile of 104 cardiovascular disease providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 197 | $291,346 |
| XareltoRivaroxaban | 141 | $208,326 |
| EntrestoSacubitril/Valsartan | 26 | $48,997 |
| Repatha SureclickEvolocumab | 24 | $30,110 |
| JardianceEmpagliflozin | 13 | $15,731 |
| Rosuvastatin Calcium | 225 | $7,728 |
| Metoprolol Succinate | 401 | $7,488 |
| Atorvastatin Calcium | 436 | $5,979 |
| Flecainide Acetate | 53 | $3,212 |
| Ranolazine ErRanolazine | 21 | $3,034 |
| Amlodipine Besylate | 286 | $2,908 |
| Valsartan | 52 | $2,892 |
| Carvedilol | 229 | $2,645 |
| Ezetimibe | 64 | $2,440 |
| ClopidogrelClopidogrel Bisulfate | 108 | $2,239 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $402 | $291,346197 claims |
| Johnson & JohnsonXarelto | $487 | $208,326141 claims |
| NovartisEntresto | $314 | $48,99726 claims |
| Boehringer IngelheimJardiance | $469 | $15,73113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 104 cardiovascular disease providers in Delaware.
Other cardiovascular disease in Newark
- Edward GoldenbergNewark$52K
- Muhammad ShakirNewark$47K
- Anthony AlfieriNewark$45K
- Sean DikdanNewark$42K
- Kirk GarrattNewark$38K
- Anthony ClayNewark$37K
- Ashish ParikhNewark$26K
- William WeintraubNewark$24K
- Wen Chi TsaiNewark$20K
- Stephen MengNewark$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.